PE20030900A1 - SALT AGONIST OF THE ß3 ADRENERGIC RECEPTOR, ITS FORMULATIONS AND ITS USES - Google Patents
SALT AGONIST OF THE ß3 ADRENERGIC RECEPTOR, ITS FORMULATIONS AND ITS USESInfo
- Publication number
- PE20030900A1 PE20030900A1 PE2003000179A PE2003000179A PE20030900A1 PE 20030900 A1 PE20030900 A1 PE 20030900A1 PE 2003000179 A PE2003000179 A PE 2003000179A PE 2003000179 A PE2003000179 A PE 2003000179A PE 20030900 A1 PE20030900 A1 PE 20030900A1
- Authority
- PE
- Peru
- Prior art keywords
- salt
- adrenergic receptor
- agonist
- formulations
- toluensulphonate
- Prior art date
Links
- 102100034159 Beta-3 adrenergic receptor Human genes 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- -1 COMPOUND p-TOLUENSULPHONATE SALT Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 235000020997 lean meat Nutrition 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000004682 monohydrates Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A SAL DE p-TOLUENSULFONATO DE (R)-2-(2-(4-OXAZOL-4-ILFENOXI)ETILAMINO)-1-PIRIDIN-3-ILETANOL), MONOHIDRATO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE LA SAL DE p-TOLUENSULFONATO DEL COMPUESTO, UN EXCIPIENTE, VEHICULO, DILUYENTE. EL COMPUESTO PUEDE SER UTIL PARA EL TRATAMIENTO DE UNA ENFERMEDAD, AFECCION, TRASTORNO MEDIADO POR EL RECEPTOR ß3 ADRENERGICO, PARA AUMENTAR EL CONTENIDO DE CARNE MAGRA EN UNA NIMAL COMESTIBLEREFERS TO (R) -2- (2- (4-OXAZOL-4-ILPHENOXY) ETHYLAMINE) -1-PYRIDIN-3-ILETHANOL), MONOHYDRATE, p-TOLUENSULPHONATE SALT. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING THE COMPOUND p-TOLUENSULPHONATE SALT, AN EXCIPIENT, VEHICLE, THINNER. THE COMPOUND MAY BE USEFUL FOR THE TREATMENT OF A DISEASE, CONDITION, DISORDER MEDIATED BY THE ß3 ADRENERGIC RECEPTOR, TO INCREASE THE CONTENT OF LEAN MEAT IN AN EDIBLE NIMAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36024802P | 2002-02-27 | 2002-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030900A1 true PE20030900A1 (en) | 2003-10-25 |
Family
ID=27766205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000179A PE20030900A1 (en) | 2002-02-27 | 2003-02-24 | SALT AGONIST OF THE ß3 ADRENERGIC RECEPTOR, ITS FORMULATIONS AND ITS USES |
Country Status (8)
| Country | Link |
|---|---|
| AR (1) | AR038603A1 (en) |
| AU (1) | AU2003248355A1 (en) |
| GT (1) | GT200300044A (en) |
| PA (1) | PA8567601A1 (en) |
| PE (1) | PE20030900A1 (en) |
| TW (1) | TW200305414A (en) |
| UY (1) | UY27678A1 (en) |
| WO (1) | WO2003072571A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9812709D0 (en) * | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
| BR0114836A (en) * | 2000-10-20 | 2003-07-01 | Pfizer Prod Inc | Beta-3 adrenergic receptor agonists and their applications |
-
2003
- 2003-02-17 WO PCT/IB2003/000575 patent/WO2003072571A1/en not_active Ceased
- 2003-02-17 AU AU2003248355A patent/AU2003248355A1/en not_active Abandoned
- 2003-02-24 PE PE2003000179A patent/PE20030900A1/en not_active Application Discontinuation
- 2003-02-25 UY UY27678A patent/UY27678A1/en not_active Application Discontinuation
- 2003-02-25 AR ARP030100606A patent/AR038603A1/en not_active Application Discontinuation
- 2003-02-26 TW TW092104035A patent/TW200305414A/en unknown
- 2003-02-26 PA PA20038567601A patent/PA8567601A1/en unknown
- 2003-02-26 GT GT200300044A patent/GT200300044A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PA8567601A1 (en) | 2003-12-10 |
| AR038603A1 (en) | 2005-01-19 |
| AU2003248355A1 (en) | 2003-09-09 |
| GT200300044A (en) | 2003-09-22 |
| TW200305414A (en) | 2003-11-01 |
| UY27678A1 (en) | 2003-10-31 |
| WO2003072571A1 (en) | 2003-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2524320T3 (en) | Composition for the prevention or treatment of disease associated with thrombus or embolus | |
| ES2547336T3 (en) | Topical composition for use for the treatment of rosacea-induced redness | |
| ES2557303T3 (en) | Therapeutic agent for spinal canal stenosis | |
| AR073606A1 (en) | METHOD OF USE OF A BACILLUS SUBTILIS CEPA TO IMPROVE ANIMAL HEALTH | |
| AR062536A1 (en) | SUBSTITUTED ACILANILIDS AND PHARMACEUTICAL COMPOSITION | |
| AR063201A1 (en) | PHARMACEUTICAL COMPOSITIONS OF ROPINIROL AND METHODS OF USE OF THE SAME | |
| AR109605A2 (en) | METHOD FOR TREATING PERIPHERAL VASCULAR DISEASES, COMPOSITION AND USE | |
| AR063136A1 (en) | MICRO- PERISTALTIC PUMP WITH INTERCHANGEABLE PUMP HEAD | |
| AR052082A1 (en) | COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH THE INCREASE OF THE SANGUINEA CONCENTRATION OF GELP -1 | |
| BRPI0408247A (en) | uses of il-23 antagonists and agonists and related reagents | |
| CR9849A (en) | GAMMA RECEPTOR AGONISTS ACTIVATED BY THE PEROXISOM PROLIFERATOR FOR THE IMPROVEMENT OF COGNITIVE FUNCTION IN PATIENTS WITH NEGATIVE APOLIPOPROTEIN E4 | |
| CL2012001233A1 (en) | Liquid pharmaceutical composition comprising 0.01-1.5 mg / ml of a glp-1 agonist that is depro36-extended-4 (1-39) -lys6-nh2 or a salt, methionine and optionally at least one excipient, free histidine; Preparation method; use to treat diabetes. | |
| CL2008003582A1 (en) | Use of a pharmaceutical composition containing cysteamine or cystamine in the preparation of a useful medicine for the treatment of non-alcoholic fatty liver disease (nafld) or non-alcoholic steatohepatitis (nash). | |
| AR056055A1 (en) | CRYSTALLINE AND HYDRATIC COMPLEXES OF 1-CHLORINE-4- (BETA-D-GLUCOPIRANOS-1-IL) -2- (4-ETINIL-BENCIL) -BENZENE | |
| AR045972A1 (en) | FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS | |
| CL2008003789A1 (en) | Carboxyl- or hydroxyl-substituted benzimidazole derivative compounds, selective modulators of the farnesoid x receptor (fxr); Preparation process; pharmaceutical composition comprising said compound; and use of the compound for the treatment of diabetes, dyslipidemia, metabolic syndrome, cancer, Alzheimer's. | |
| AR070025A1 (en) | USE OF DERIVATIVES OF 1-AMINO-ALQUILCICLOHEXANO FOR THE TREATMENT OF COCLEAR TINNITUS AND PHARMACEUTICAL COMPOSITION | |
| AR112284A1 (en) | COMBINATION INCLUDING PALBOCICLIB AND ACID 6- (2,4-DICHLOROPHENIL) -5- [4 - [(3S) -1- (3-FLUOROPROPYL) PYRROLIDIN-3-IL] OXIPHENIL] -8,9-DIHIDRO-7H- BENZO [7] ANNULENE-2-CARBOXYL | |
| AR039164A1 (en) | VENLAFAXINE SALTS OF LOW WATER SOLUBILITY | |
| CL2011000798A1 (en) | Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation. | |
| CL2011000806A1 (en) | Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation. | |
| WO2003060475A3 (en) | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues | |
| PE20070521A1 (en) | 7- [2- [4- (6-FLUORO-3-METHYL-1,2-BENZYSOXAZOL-5-IL) -1-PIPERAZINYL] ETHYL] -2- (1-PROPINYL) -7H-PIRAZOLE- [4, 3-E] - [1,2,4] -TRIAZOL- [1,5-C] -PYRIMIDIN-5-AMINE AS ANTAGONIST OF THE ADENOSINE A2a RECEPTOR | |
| AR060264A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING LACTATE AND CALCIUM, USES OF SUCH COMPOSITION AND PREPARATION METHOD | |
| CO6280474A2 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF EFFECTIVE EJACULATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |